Costs of informal care for heart failure substantial in the USA

2015 ◽  
Vol 719 (1) ◽  
pp. 11-11
Keyword(s):  
1992 ◽  
Vol 30 (16) ◽  
pp. 61-63

In the USA, heart failure affects about 1% of people in their 50s, rising to 10% of those in their 80s,1 and the figure is probably higher in the UK. The symptoms are distressing, usually relentless, and associated with mortality rates four to eight times greater than those in the general population of the same age.1 This article reviews the treatment of uncomplicated heart failure, concentrating on its management in general practice.


2021 ◽  
Vol 17 ◽  
Author(s):  
Tuoyo O Mene-Afejuku ◽  
Abayomi O Bamgboje ◽  
Modele O Ogunniyi ◽  
Ola Akinboboye ◽  
Uzoma N Ibebuogu

Background: Heart failure (HF) is a global public health problem which affects over 23 million people worldwide. The prevalence of HF is higher among seniors in the USA and other developed countries. Ventricular arrhythmias (VAs) account for 50% of deaths among patients with HF. We aim to elucidate on the factors associated with VAs among seniors with HF, as well as therapies that may improve outcomes. Methods: PubMed, Web of Science, Scopus, Cochrane Library databases, Science Direct, and Google Scholar were searched using specific key words. The reference lists of relevant articles were searched for additional studies related to HF and VAs among seniors as well as associated outcomes. Results: The prevalence of VAs increases with worsening HF. 24-hour Holter electrocardiogram may be useful in risk stratifying patients for device therapy if they do not meet the criterion of low ventricular ejection fraction. Implantable cardiac defibrillators (ICDs) are superior to anti-arrhythmic drugs in reducing mortality in patients with HF. Guideline directed medical therapy (GDMT) together with device therapy to reduce symptoms may be required. In general, the proportion of seniors on GDMT is low. A combination of ICDs and cardiac resynchronization therapy may improve outcomes in select patients. Conclusion: Seniors with HF and VAs have a high mortality even with the use device therapy and GDMT. The holistic effect of device therapy on outcomes among seniors with HF is equivocal. More studies focused on seniors with advanced HF as well as therapeutic options is therefore required.


2009 ◽  
Vol 1 ◽  
pp. CMT.S2211
Author(s):  
Frances McManus ◽  
John Connell

Suppression of the Renin-Angiotensin-Aldosterone system (RAAS) is an established intervention in the management of cardiovascular disease. Large, randomized controlled trials have provided a sound evidence base for the use of mineralocorticoid receptor antagonists to block the end product of the RAAS in the treatment of heart failure. However, the place for mineralocorticoid blockade in the treatment of hypertension is less well defined and lacking a strong evidence base. The main indication for the use of this strategy in hypertension is as a third line agent in the treatment of refractory hypertension. The most widely used mineralocorticoid receptor antagonist, spironolactone, is associated with dose related sexual side effects, limiting its use in clinical practice. Eplerenone, the selective mineralocorticoid receptor antagonist, is a promising cardiovascular drug licensed for the treatment of heart failure in Europe and heart failure and hypertension in the USA. It effectively blocks the mineralocorticoid receptor without the unpleasant sexual side effect profile of spironolactone. We review the use of eplerenone, a selective mineralocorticoid receptor antagonist in the treatment of hypertension; discuss its mechanism of action, safety profile as well as its current place in therapy.


2008 ◽  
Vol 61 (4) ◽  
pp. 373-383 ◽  
Author(s):  
Alexander M. Clark ◽  
Margaret E. Reid ◽  
Caroline E. Morrison ◽  
Simon Capewell ◽  
David L. Murdoch ◽  
...  

2010 ◽  
Vol 8 (2) ◽  
pp. 279-290
Author(s):  
Charles R Salters ◽  
Alison L Bailey ◽  
Thomas F Whayne

2021 ◽  
pp. 56-66
Author(s):  
Wasiq Sheikh ◽  
Malik Bilal Ahmed ◽  
Anshul Parulkar ◽  
Tamara Lhungay ◽  
Esseim Sharma ◽  
...  

Background: The Hospital Readmission Reduction Program (HRRP) sought to reduce readmissions by penalising centres with readmissions above the national average, and heart failure (HF) is the leading driver of the readmission penalty. Recent Medicare analyses question the effectiveness of this strategy. This study evaluated the efficacy of HRRP by utilising large national datasets and is the first to analyse based on heart failure subtypes. Methods: Aggregate data was used from the National Inpatient Sample (NIS) to study mortality and the National Readmissions Database (NRD) to study readmissions. Both included all payer-types and were stratified by heart failure subtype and time (pre- and post-HRRP implementation). Results: Patients with HF with preserved ejection fraction (HFpEF) tended to be older females with a higher proportion of comorbidities compared to patients with HF with reduced ejection fraction (HFrEF). In the post-HRRP period, readmission rates decreased for HFrEF (21.4% versus 22.3%, p<0.001) and HFpEF (21.2% versus 22.4%, p<0.001); readmission rates for the two subtypes were not statistically different compared to the other. Post-HRRP, inpatient mortality was consistent for HFrEF (2.8% versus 2.8%, p=0.087), but decreased for HFpEF (2.4% versus 2.5%, p=0.029). There were no significant differences noted in average length of stay. Patients with HFrEF were more frequently discharged to short-term hospitals or home with home healthcare, and patients with HFpEF were discharged to skilled nursing facilities more often. Estimated inpatient costs decreased in both subtypes post-HRRP, but readmission costs were higher for HFrEF. Conclusions: This study suggests that HRRP was associated with minimal change in readmission and inpatient mortality.


Author(s):  
Mohammad A. Abu Sa'aleek ◽  
Bader T. Al zawahra

Heart failure is considered as a chronic disease and the management of such condition is complex and challenging. Nurses play a significant role in managing heart failure by enhancing self-care practices among patients. This paper aims to evaluate evidence from the literature regarding nurses level of knowledge about the educational principles in heart failure. The nine selected studies included a total number of 1181 patients. These studies were conducted in the USA and Europe from 2002 until 2019.the uniqueness of those selected studies that all the authors use the same instrument titled “nurses knowledge of heart failure education principles”. The results revealed that there was an inconsistency in the level of knowledge among nurses in hospital-based, ambulatory, primary care or home care settings. More randomized studies are needed to solve this discrepancy. The level of knowledge ranged from (60.4-79.85%). Six topics have been identified as areas of weakness in which education is needed. Educating nurses in different settings is the gold stander to raise their level of knowledge which in turn will be in a better position to provide a high level of education for patients in order to alleviate their suffering, improve the quality of life and reduce the frequent hospitalization.


Sign in / Sign up

Export Citation Format

Share Document